Query author contributions in Reactome
Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.
If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.
Details on Person ERBB2 signaling is inhibited by binding of ERBB2 to ERBB2-di...
| Class:Id | Summation:9652268 |
|---|---|
| _displayName | ERBB2 signaling is inhibited by binding of ERBB2 to ERBB2-di... |
| _timestamp | 2019-10-30 13:39:07 |
| created | [InstanceEdit:9652267] Orlic-Milacic, Marija, 2019-06-28 |
| literatureReference | [LiteratureReference:9634297] The effects of trastuzumab on HER2-mediated cell signaling in CHO cells expressing human HER2 [LiteratureReference:1227966] Comparison of 3D and 2D tumor models reveals enhanced HER2 activation in 3D associated with an increased response to trastuzumab [LiteratureReference:9652354] p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor [LiteratureReference:9652351] Humanization of an anti-p185HER2 antibody for human cancer therapy |
| modified | [InstanceEdit:9652372] Orlic-Milacic, Marija, 2019-06-28 [InstanceEdit:9656314] Orlic-Milacic, Marija, 2019-07-31 [InstanceEdit:9665224] Orlic-Milacic, Marija, 2019-10-30 |
| text | ERBB2 signaling is inhibited by binding of ERBB2 to ERBB2-directed therapeutic recombinant antibody trastuzumab (herceptin), used an anti-cancer therapeutic in tumors that overexpress ERBB2 (Hudziak et al. 1989, Carter et al. 1992). Trastuzumab does not prevent homodimerization of overexpressed ERBB2 and remains bound to ERBB2 (HER2) homodimers (Maadi et al. 2018). Autophosphorylation of ERBB2 homodimers and downstream signaling is inhibited by trastuzumab (Pickl and Ries 2009). It is unclear whether trastuzumab mainly acts through endocytosis-mediated downregulation of ERBB2 receptor on the cell surface or through interference with the kinase activity. The mechanism of trastuzumab action may also rely on antibody-dependent cellular cytotoxicity (ADCC) (Maadi et al. 2008). |
| (summation) | [Reaction:9652277] ERBB2 binds trastuzumab [Homo sapiens] |
| [Change default viewing format] | |
No pathways have been reviewed or authored by ERBB2 signaling is inhibited by binding of ERBB2 to ERBB2-di... (9652268)
